Overview of Services

The generation and analysis of genetically modified mice, including transgenic and knockout animals, is an essential technology for cancer research. The Genetically Modified Mouse Models Shared Resource (GMMMSR) makes these powerful technologies available to all Cancer Center members and others.

Services include:

• Full gene targeting service. Let us know the mouse models you want to generate, and we take care of the rest for you. Guaranteed delivery of heterozygous mice in 8-10 months. 100% refund guarantee on this service. We perform gene targeting in C57BL/6J, C57BL/6N, 129S6/SvEvTac, and 129B6 hybrid ES cells. Our C57BL/6 ES lines are robust in producing germline chimeras.
• Full CRISPR gene editing service.  GMMMSR designs/executes the CRISPR gene editing approach and delivers mice with desired editing validated by Sanger sequencing.

• CRISPR/Cas9 Genome Editing Services. GMMMSR provides comprehensive CRISPR/Cas9 genome engineering in mice, including INDEL generation, targeted deletions, point mutation or epitope-tag knock-ins, and large-fragment knock-ins via the Easi-CRISPR platform. Complimentary consultation is available for CRISPR design. Clients design and supply all CRISPR reagents; GMMMSR performs microinjection of CRISPR components into fertilized mouse oocytes. This service includes a performance guarantee: production of either ten live pups or two CRISPR-positive founders, whichever is achieved first. For projects targeting genes in which the null allele is associated with embryonic lethality, GMMMSR follows a modified injection strategy to maximize recovery of viable edited founders. In the initial injection session, CRISPR RNP complexes will be delivered at 50% of the standard concentration, while the donor template will be delivered at full strength. If a second injection round is required, CRISPR RNP will be reduced to 10% of the standard concentration, with the donor template again delivered at full strength. Completion of these two injection attempts constitutes fulfillment of the CRISPR service request.

• Production of transgenic mice by pronuclear DNA microinjection and embryo transfer.
• Production of chimeric mice by blastocyst injection of genetically modified ES cells and embryo transfer, which is part of the procedure of producing knockout or knockin mice.
• Gene targeting, which involves the electroporation of a targeting vector provided by our client into pluripotent mouse embryonic stem (ES) cells. Screening of targeted ES clones is done by clients. C57BL/6J, C57BL/6N, 129S6/SvEvTac, and 129B6 hybrid ES cells are available for this service.
• Embryonic Stem (ES) cell line derivation.
• Consultation and advice on vector and experimental design for experiments using transgenic and knockout mice.

Leadership

Jianwen Que, MD, Ph.D, Scientific Director

Chyuan-Sheng (Victor) Lin, Ph.D., Technical Director

Location and Hours of Operation

Links and Resources

1. Core Website

2. Institute for Comparative Medicine
3. Frequently Asked Questions
   

Contacts